Pharmacokinetic and tissue distribution studies of the photosensitizer bis(di-isobutyl octadecylsiloxy)silicon 2,3-naphthalocyanine (isoBOSINC) in normal and tumor-bearing rats.
Bis(di-isobutyl octadecylsiloxy)silicon 2,3-naphthalocyanine (isoBOSINC) is a representative of a group of naphthalocyanine derivatives with spectral and photophysical properties that make them attractive candidates for photodynamic therapy (PDT). Tissue distributions were studied in normal and in tumor-bearing rats as a function of time following intravenous injection of isoBOSINC as a suspension in 10% Tween 80 in saline. The dose studied was 0.25 mg/kg of body weight. The compound isoBOSINC was isolated from several tissues and organs, as well as tumors and peritumoral muscles and skin, and quantitated by a high-performance liquid chromatographic technique. The tumor model, an N-(4-[5-nitro-2-furyl]-2-thiazolyl)formamide (FANFT)-induced urothelial cell carcinoma, was transplanted into the hind legs of Fischer 344 rats. The dye was retained in tumors at higher concentrations than in all tissues and organs examined, except for spleen and liver. The highest concentration ratio of dye in tumor versus peritumoral muscle (24.5) occurred 9 h after injection. Serum clearance of isoBOSINC showed similar kinetic behavior for both groups of rats, with a t 1/2 of elimination of approximately 10 h. At 7 and 14 days postinjection, the levels of dye found in testes were generally higher than in most other tissues, except spleen and liver. Concentrations of isoBOSINC were either very low or not detectable in rat brain. Trace amounts of the dye were excreted in the urine, and by day 14 approximately 17% of the dose was accounted for in the feces. The significant levels of the drug in tumors, as well as the excellent ratios of tumor-to-muscle concentration observed, have promising implications for PDT of tumors.
Zuk
M M
MM
Research Department, St. Vincent Medical Center, Toledo, OH 43608.
Rihter
B D
BD
Kenney
M E
ME
Rodgers
M A
MA
Kreimer-Birnbaum
M
M
D000818:Animals; D008297:Male; D008665:Metalloporphyrins / Q000493:pharmacokinetics*; D009132:Muscles / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000378:metabolism*; D017646:Organosilicon Compounds / Q000493:pharmacokinetics*; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics*; D051381:Rats; D011916:Rats, Inbred F344; D012867:Skin / Q000378:metabolism; D014018:Tissue Distribution
D008665:Metalloporphyrins; D017646:Organosilicon Compounds; D011838:Radiation-Sensitizing Agents; C072758:bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine